Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19,711,628
-
Total 13F shares
-
11,367,208
-
Share change
-
-1,451,836
-
Total reported value
-
$44,104,000
-
Put/Call ratio
-
32%
-
Price per share
-
$3.88
-
Number of holders
-
51
-
Value change
-
-$5,935,339
-
Number of buys
-
19
-
Number of sells
-
37
Institutional Holders of Viracta Therapeutics, Inc. - Common Stock (VIRX) as of Q2 2022
As of 30 Jun 2022,
Viracta Therapeutics, Inc. - Common Stock (VIRX) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,367,208 shares.
The largest 10 holders included
BVF INC/IL, CITADEL ADVISORS LLC, VANGUARD GROUP INC, Laurion Capital Management LP, Samsara BioCapital, LLC, MAI Capital Management, BlackRock Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., MILLENNIUM MANAGEMENT LLC, and Aisling Capital Management LP.
This page lists
51
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.